[
  {
    "ts": null,
    "headline": "Janus Henderson Global Life Sciences Fund Q4 2024 Commentary",
    "summary": "The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=10b10afe2a805029d7ce2f9c8b1ec10ce14300270ce9d50ee7971586c5474449",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739392800,
      "headline": "Janus Henderson Global Life Sciences Fund Q4 2024 Commentary",
      "id": 132698753,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1322205585/image_1322205585.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=10b10afe2a805029d7ce2f9c8b1ec10ce14300270ce9d50ee7971586c5474449"
    }
  },
  {
    "ts": null,
    "headline": "IGA: Good Diversification And Fully-Covered Distribution (Rating Upgrade)",
    "summary": "Voya Global Advantage and Premium Opportunity Fund has a 10.74% yield, diversification benefits, and well-covered distributions. Click for my IGA CEF update.",
    "url": "https://finnhub.io/api/news?id=2ba8d05d868d19834abb8a5b6fdaa46772c05175fc15d368f4cc2a0552dcd71b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739377566,
      "headline": "IGA: Good Diversification And Fully-Covered Distribution (Rating Upgrade)",
      "id": 132689669,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1302522750/image_1302522750.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Voya Global Advantage and Premium Opportunity Fund has a 10.74% yield, diversification benefits, and well-covered distributions. Click for my IGA CEF update.",
      "url": "https://finnhub.io/api/news?id=2ba8d05d868d19834abb8a5b6fdaa46772c05175fc15d368f4cc2a0552dcd71b"
    }
  },
  {
    "ts": null,
    "headline": "Xilio Therapeutics Shares Surge Premarket on AbbVie Deal",
    "summary": "Xilio Therapeutics Shares Surge Premarket on AbbVie Deal",
    "url": "https://finnhub.io/api/news?id=16a45286150359a69b8351c11fa83a27287c0909bf6a5980df5258a5b204e010",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739348760,
      "headline": "Xilio Therapeutics Shares Surge Premarket on AbbVie Deal",
      "id": 132681515,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "Xilio Therapeutics Shares Surge Premarket on AbbVie Deal",
      "url": "https://finnhub.io/api/news?id=16a45286150359a69b8351c11fa83a27287c0909bf6a5980df5258a5b204e010"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie, Xilio Therapeutics Set Collaboration, Option-To-License Agreement",
    "summary": "AbbVie, Xilio Therapeutics Set Collaboration, Option-To-License Agreement",
    "url": "https://finnhub.io/api/news?id=69c55745a48ed71df24538ebeba07ed172dd7f041a13df854a31fb3657e16548",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739347020,
      "headline": "AbbVie, Xilio Therapeutics Set Collaboration, Option-To-License Agreement",
      "id": 132681516,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie, Xilio Therapeutics Set Collaboration, Option-To-License Agreement",
      "url": "https://finnhub.io/api/news?id=69c55745a48ed71df24538ebeba07ed172dd7f041a13df854a31fb3657e16548"
    }
  }
]